ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1028
-0,53%
Bitcoin
66.892,56
2,53%
Brent Oil
83,735
0,64%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. EQRx Inc (EQRX)

  7. EQRx Inc (EQRX) Notícias

EQRX

EQRx (EQRX)

EQRx Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:EQRX
DataHoraFonteTítuloCódigoCompanhia
20/11/202318:00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:EQRXEQRx Inc
20/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EQRXEQRx Inc
09/11/202318:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQRXEQRx Inc
09/11/202318:05Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EQRXEQRx Inc
09/11/202318:03Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EQRXEQRx Inc
09/11/202311:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQRXEQRx Inc
08/11/202313:30GlobeNewswire Inc.Revolution Medicines and EQRx Stockholders Approve EQRx AcquisitionNASDAQ:EQRXEQRx Inc
06/11/202318:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQRXEQRx Inc
01/11/202309:02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EQRXEQRx Inc
01/11/202308:59Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:EQRXEQRx Inc
01/08/202308:00GlobeNewswire Inc.Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional CapitalNASDAQ:EQRXEQRx Inc
08/05/202318:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:EQRXEQRx Inc
08/05/202317:01GlobeNewswire Inc.EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial ResultsNASDAQ:EQRXEQRx Inc
27/04/202309:00GlobeNewswire Inc.EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023NASDAQ:EQRXEQRx Inc
13/03/202310:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EQRXEQRx Inc
23/02/202319:31Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:EQRXEQRx Inc
23/02/202318:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:EQRXEQRx Inc
23/02/202309:00GlobeNewswire Inc.EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate ProgressNASDAQ:EQRXEQRx Inc
22/02/202318:09Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:EQRXEQRx Inc
09/02/202313:29Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:EQRXEQRx Inc
03/01/202310:00GlobeNewswire Inc.EQRx to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:EQRXEQRx Inc
19/12/202210:00GlobeNewswire Inc.EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung CancerNASDAQ:EQRXEQRx Inc
02/12/202210:00GlobeNewswire Inc.EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung CancerNASDAQ:EQRXEQRx Inc
25/11/202218:08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:EQRXEQRx Inc
10/11/202209:00GlobeNewswire Inc.EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial ResultsNASDAQ:EQRXEQRx Inc
07/11/202210:00GlobeNewswire Inc.EQRx to Participate in the Jefferies 2022 London Healthcare ConferenceNASDAQ:EQRXEQRx Inc
28/10/202209:00GlobeNewswire Inc.EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022NASDAQ:EQRXEQRx Inc
12/08/202217:10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:EQRXEQRx Inc
12/08/202217:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:EQRXEQRx Inc
11/08/202208:00GlobeNewswire Inc.EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate ProgressNASDAQ:EQRXEQRx Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:EQRX

Seu Histórico Recente

BIT
UC0W3A
Unicredit Bank
ASX
BCD
Beaconsfield Gold
TSXV
SYR.H
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados